Covid19-Sources

The COVID-19 pandemic posed an unprecedented global threat to healthcare systems, causing delays in colorectal cancer (CRC) diagnoses. This study aims…

Yes. Here's an electron microscope image of salt particles on the fibes of a KN95 by . The image is of a NIOSH-type salt loading test of the melt blown filter media used in Zimi 9541. The "big" crystals are about 1.5 microns.… — Gerard Hughes ( @ghhughes@zeroes.ca ) (@ghhughes)

A clinical trial with long-term follow-up found that administering BCG vaccine during the active phase of COVID-19 appeared to offer protection against long COVID symptoms.

Over the last few years, COVID-19 has attracted medical attention both in terms of healthcare system reorganization and research. Among the different cardiovascular complications of the SARS-CoV-2 infection, cardiac arrhythmias represent an important clinical manifestation requiring proper therapy both in the acute and post-acute phase. The multiparametric in-hospital monitoring of COVID-19 patients frequently detects new-onset or recurrent cardiac arrhythmias. As many patients are monitored remotely from cardiology departments, this setting calls for proper arrhythmia interpretation and management, especially in critically ill patients in the intensive care unit. From this perspective, the possible pathophysiologic mechanisms and the main clinical manifestations of brady- and tachyarrhythmias in COVID-19 patients are briefly presented. The progressively increasing body of evidence on pathophysiology helps to identify the reversible causes of arrhythmias, better clarify the setting in which they occur, and establish their impact on prognosis, which are of paramount importance to orient decision making. Despite the accumulating knowledge on this disease, some dilemmas in the management of these patients may remain, such as the need to implant in the acute or post-acute phase a permanent pacemaker or cardioverter/defibrillation in patients presenting with brady- or tachyarrhythmias and lifelong oral anticoagulation in new-onset atrial fibrillation detected during SARS-CoV-2 infection.

Das charakteristische Spike-Protein des COVID-19-Erregers lässt sich mitunter auch Jahre nach der Infektion noch im Gehirn finden, zeigt eine neue Studie. Diese Ansammlung erklärt womöglich neurologische Langzeitfolgen von COVID-19.

Scientific Reports - Astodrimer sodium nasal spray forms a barrier to SARS-CoV-2 in vitro and preserves normal mucociliary function in human nasal epithelium

BackgroundThe COVID-19 pandemic has demonstrated the benefits and advantages of RNA technology in combination with lipid nanoparticle (LNP) delivery systems for

Berlin – Die aktuellen Therapiemöglichkeiten vom Post-COVID-Syndrom (PCS) sind vor allem symptomatisch und off Label. Allerdings gibt es aktuell einige in... #PCS #ME/CFS #longcovid

Individuals with COVID-19 infection are more likely to develop cardiovascular complications compared to influenza and RSV, highlighting the need for higher index of suspicion and prompt treatment, as well as steps to limit infection and transmission of this virus in children.

Nature Microbiology - SARS-CoV-2 adaptation and evolution led to stronger innate immune suppression by increasing expression of Orf6 in Omicron subvariants.

Objective To compare the effectiveness of interventions for the management of long covid (post-covid condition). Design Living systematic review. Data sources Medline, Embase, CINAHL, PsycInfo, Allied and Complementary Medicine Database, and Cochrane Central Register of Controlled Trials from inception to December 2023. Eligibility criteria Trials that randomised adults (≥18 years) with long covid to drug or non-drug interventions, placebo or sham, or usual care. Results 24 trials with 3695 patients were eligible. Four trials (n=708 patients) investigated drug interventions, eight (n=985) physical activity or rehabilitation, three (n=314) behavioural, four (n=794) dietary, four (n=309) medical devices and technologies, and one (n=585) a combination of physical exercise and mental health rehabilitation. Moderate certainty evidence suggested that, compared with usual care, an online programme of cognitive behavioural therapy (CBT) probably reduces fatigue (mean difference −8.4, 95% confidence interval (CI) −13.11 to −3.69; Checklist for Individual Strength fatigue subscale; range 8-56, higher scores indicate greater impairment) and probably improves concentration (mean difference −5.2, −7.97 to −2.43; Checklist for Individual Strength concentration problems subscale; range 4-28; higher scores indicate greater impairment). Moderate certainty evidence suggested that, compared with usual care, an online, supervised, combined physical and mental health rehabilitation programme probably leads to improvement in overall health, with an estimated 161 more patients per 1000 (95% CI 61 more to 292 more) experiencing meaningful improvement or recovery, probably reduces symptoms of depression (mean difference −1.50, −2.41 to −0.59; Hospital Anxiety and Depression Scale depression subscale; range 0-21; higher scores indicate greater impairment), and probably improves quality of life (0.04, 95% CI 0.00 to 0.08; Patient-Reported Outcomes Measurement Information System 29+2 Profile; range −0.022-1; higher scores indicate less impairment). Moderate certainty evidence suggested that intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 1.12 to 6.48; SF-36 physical component summary score; range 0-100; higher scores indicate less impairment). No compelling evidence was found to support the effectiveness of other interventions, including, among others, vortioxetine, leronlimab, combined probiotics-prebiotics, coenzyme Q10, amygdala and insula retraining, combined L-arginine and vitamin C, inspiratory muscle training, transcranial direct current stimulation, hyperbaric oxygen, a mobile application providing education on long covid. Conclusion Moderate certainty evidence suggests that CBT and physical and mental health rehabilitation probably improve symptoms of long covid. Systematic review registration Open Science Framework . Readers’ note This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. Additional data are available at .

The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by December 2021. Risk of severe outcomes associated with Omicron infections, as compared to earlier SARS-CoV-2 variants, remains unclear. Methods: We analyzed clinical and epidemiologic data from cases testing positive for SARS-CoV-2 infection within the Kaiser Permanente Southern California healthcare system from November 30, 2021 to January 1, 2022, using S gene target failure (SGTF) as assessed by the ThermoFisher TaqPath ComboKit assay as a proxy for Omicron infection. We fit Cox proportional hazards models to compare time to any hospital admission and hospital admissions associated with new-onset respiratory symptoms, intensive care unit (ICU) admission, mechanical ventilation, and mortality among cases with Omicron and Delta (non-SGTF) variant infections. We fit parametric competing risk models to compare lengths of hospital stay among admitted cases with Omicron and Delta variant infections. Results: Our analyses included 52,297 cases with SGTF (Omicron) and 16,982 cases with non-SGTF (Delta [B.1.617.2]) infections, respectively. Hospital admissions occurred among 235 (0.5%) and 222 (1.3%) of cases with Omicron and Delta variant infections, respectively. Among cases first tested in outpatient settings, the adjusted hazard ratios for any subsequent hospital admission and symptomatic hospital admission associated with Omicron variant infection were 0.48 (0.36-0.64) and 0.47 (0.35-0.62), respectively. Rates of ICU admission and mortality after an outpatient positive test were 0.26 (0.10-0.73) and 0.09 (0.01-0.75) fold as high among cases with Omicron variant infection as compared to cases with Delta variant infection. Zero cases with Omicron variant infection received mechanical ventilation, as compared to 11 cases with Delta variant infections throughout the period of follow-up (two-sided p0.001). Median duration of hospital stay was 3.4 (2.8-4.1) days shorter for hospitalized cases with Omicron variant infections as compared to hospitalized patients with Delta variant infections, reflecting a 69.6% (64.0-74.5%) reduction in hospital length of stay. Conclusions: During a period with mixed Delta and Omicron variant circulation, SARS-CoV-2 infections with presumed Omicron variant infection were associated with substantially reduced risk of severe clinical endpoints and shorter durations of hospital stay.

Introduction: COVID-19 (SARS-CoV-2) has been linked to organ damage in humans since its worldwide outbreak. It can also induce severe sperm damage, according...

— Ali Max Erturk (@erturklab)

Disrupted endothelial function underlies the multiorgan complications of COVID-19

Disseminated intravascular coagulation (DIC) is an acquired condition that develops as a complication of systemic and sustained cell injury in conditions such as sepsis and trauma. It represents major dysregulation and increased thrombin generation ...

COVID-19 Update 67 with critical care specialist and pulmonologist Roger Seheult, MD of https://www.medcram.com/?utm_source=Youtube&utm_medium=Video&utm_campaign=Video+Link+Clicks&utm_term=Coronavirus+Pandemic+Update+67%3A+COVID-19+Blood+Clots+-+Race%2C+Blood+Types%2C+%26+Von+Willebrand+Factor&utm_content=JOlVkES_kC8 After an update of global coronavirus infections and deaths, Dr. Seheult continues his review of journals and illustrates more of the possible pathway for blood clot (thrombosis) formation in COVID-19. See how oxidative stress of the endothelium (lining of the blood vessels), Von Willebrand factor, racial differences, and blood types may have a significant effect on COVID-19 severity and fatality rates. Links referenced in this video: Johns Hopkins - https://coronavirus.jhu.edu/map.html https://www.worldometers.info/coronavirus/ Karger - https://www.karger.com/Article/PDF/73600 Pathophysiology of Haemostasis and Thrombosis - https://www.ncbi.nlm.nih.gov/pubmed/13679676 Thrombosis Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156948/ Intechopen - https://www.intechopen.com/books/endothelial-dysfunction-old-concepts-and-new-challenges/endothelial-cell-von-willebrand-factor-secretion-in-health-and-cardiovascular-disease Science Alert - https://www.sciencealert.com/paper-suggests-certain-blood-types-might-be-slightly-more-susceptible-to-covid-19 medRxiv - https://www.medrxiv.org/content/10.1101/2020.03.11.20031096v2.full.pdf Thrombosis Journal - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042969/ Journal of Thrombosis and Haemostasis - https://www.ncbi.nlm.nih.gov/pubmed/32220112 CDC - https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html Some previous videos from this series (visit MedCram.com for the full series): -Coronavirus Pandemic Update 66: ACE-Inhibitors and ARBs - Hypertension Medications with COVID-19 https://youtu.be/OudhmwulJHY -Coronavirus Pandemic Update 65: COVID-19 and Oxidative Stress (Prevention & Risk Factors) https://youtu.be/gzx8LH4Fjic -Coronavirus Pandemic Update 64: Remdesivir COVID-19 Treatment Update https://youtu.be/Z2hfGcTokiY -Coronavirus Pandemic Update 63: Is COVID-19 a Disease of the Endothelium (Blood Vessels and Clots)? https://youtu.be/Aj2vB_VITXQ - Coronavirus Pandemic Update 62: Treatment with Famotidine (Pepcid)? https://youtu.be/DtPwfihjyrY - Coronavirus Pandemic Update 61: Blood Clots & Strokes in COVID-19; ACE-2 Receptor; Oxidative Stress https://youtu.be/22Bn8jsGI54 - Coronavirus Pandemic Update 60: Hydroxychloroquine Update; NYC Data; How Widespread is COVID-19? https://youtu.be/fn2yk5SbGiw - Coronavirus Pandemic Update 59: Dr. Seheult's Daily Regimen (Vitamin D, C, Zinc, Quercetin, NAC) https://youtu.be/NM2A2xNLWR4 - Coronavirus Pandemic Update 58: Testing; Causes of Hypoxemia in COVID-19 (V/Q vs Shunt vs Diffusion) https://youtu.be/nO4xgcIaPeA - Coronavirus Pandemic Update 57: Remdesivir Treatment Update and Can Far-UVC Disinfect Public Spaces? https://youtu.be/2U4DAQ3kjRs - Coronavirus Pandemic Update 56: What is “Forest Bathing” & Can It Boost Immunity Against Viruses? https://youtu.be/PgDjVEpEOdQ - Coronavirus Pandemic Update 55: How COVID-19 Infection Attacks The Immune System & Differs From HIV: https://youtu.be/8NffZAGELGg - Coronavirus Pandemic Update 54: COVID-19 Antibody vs. PCR Testing; When to Relax Social Distancing?: https://youtu.be/kgzFAdYwYLM - Coronavirus Pandemic Update 53: Anticoagulation; Can Mechanical Ventilation Make COVID 19 Worse?: https://youtu.be/o8aG63yigjA - Coronavirus Pandemic Update 52: Ivermectin Treatment; Does COVID-19 Attack Hemoglobin?: https://youtu.be/qc6VV7ue4cE - Coronavirus Pandemic Update 51: State by State Projections; Ultrasound to Diagnose COVID19 Pneumonia: https://youtu.be/E7MufS6dnJw - Coronavirus Pandemic Update 50: Dip in Daily New Deaths; Research on Natural Killer Cells & COVID-19: https://youtu.be/fya6Zwxch88 - How Coronavirus Kills: Acute Respiratory Distress Syndrome (ARDS) & Treatment: https://youtu.be/okg7uq_HrhQ Many other videos on COVID-19 (coronavirus outbreak, corona virus symptoms, influenza, coronavirus epidemic) and other medical topics (ECG Interpretation, strokes, thrombosis, pulmonary embolism, myocardial infarction, hypercoagulation, hypertension, anticoagulation, DKA, acute kidney injury, influenza, measles, mechanical ventilation, etc.) at MedCam.com Speaker: Roger Seheult, MD Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine. MedCram provides videos to a variety of medical schools, education programs, and institutions (please contact us at customers@medcram.com if you are interested) Media Contact: customers@medcram.com Media contact info: https://bit.ly/43xNw6z MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor. #COVID19 #SARSCoV2 #Coronavirus

Berlin – Die Überwachung bestimmter Krankheitserreger im Abwasser in Deutschland soll trotz der vorläufigen Haushaltsführung im Jahr 2025 weitergehen. „Das... #Abwassermonitoring #SARS-CoV-2 #Influenza

For parents of a child with Long Covid, following last week's focus on FII Awareness, our blog will outline how and why allegations of Fabricated and Induced Illness happen and what you can do if you are in this situation.Firstly know that you are not alone - Long Covid Kids is aware that a number of families have faced or are facing allegations of FIIAs a Charity that supports families with children and young people with Long Covid, we are aware that some professionals may raise concerns about

Somatic symptom and related disorders (SSRDs) pose significant challenges in paediatric health care due to their impacts on child and adolescent well-being, functioning, and family systems. This statement offers comprehensive guidance to health care providers on the assessment and management of SSRDs as well as communication strategies for clinical encounters. Specific SSRD diagnoses are outlined along with common clinical presentations and recommended approaches to medical investigations and patient/family communication early in the diagnostic journey. Evidence-based treatments for SSRDs once…

Nature Immunology - SARS-CoV-2 has been shown to induce IL-1β-mediated neuroinflammation in humans and rodent models. Klein and colleagues show that low-dose COVID-19 vaccination prevents...

Bone Research - Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Post-COVID-19 condition (also known as long COVID) is generally defined as symptoms persisting for 3 months or more after acute COVID-19. Long COVID can affect multiple organ systems and lead to severe and protracted impairment of function as a result of organ damage. The burden of this disease, both on the individual and on health systems and national economies, is high. In this interdisciplinary Review, with a coauthor with lived experience of severe long COVID, we sought to bring together multiple streams of literature on the epidemiology, pathophysiology (including the hypothesised mechanisms of organ damage), lived experience and clinical manifestations, and clinical investigation and management of long COVID.

Prof Trish Greenhalgh explains the findings of her recent comprehensive Lancet review of Long Covid

BACKGROUND: COVID-19 is associated with acute risk of major adverse cardiac events (MACE), including myocardial infarction, stroke, and mortality (all-cause). However, the duration and underlying determinants of heightened risk of cardiovascular disease and MACE post–COVID-19 are not known. METHODS: Data from the UK Biobank was used to identify COVID-19 cases (n=10 005) who were positive for polymerase chain reaction (PCR+)-based tests for SARS-CoV-2 infection (n=8062) or received hospital-based International Classification of Diseases version-10 (ICD-10) codes for COVID-19 (n=1943) between February 1, 2020 and December 31, 2020. Population controls (n=217 730) and propensity score—matched controls (n=38 860) were also drawn from the UK Biobank during the same period. Proportional hazard models were used to evaluate COVID-19 for association with long-term (1000 days) risk of MACE and as a coronary artery disease risk equivalent. Additional analyses examined whether COVID-19 interacted with genetic determinants to affect the risk of MACE and its components. RESULTS: The risk of MACE was elevated in COVID-19 cases at all levels of severity (HR, 2.09 [95% CI, 1.94–2.25]; P